Edition:
United Kingdom

People: Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

0.55USD
17 Jul 2019
Change (% chg)

$0.00 (+0.93%)
Prev Close
$0.54
Open
$0.56
Day's High
$0.56
Day's Low
$0.55
Volume
1,952
Avg. Vol
132,184
52-wk High
$1.87
52-wk Low
$0.51

Rombotis, Spiro 

Mr. Spiro George Rombotis serves as President, Chief Executive Officer, Director of Cyclacel Pharmaceuticals Inc. Mr. Rombotis has served as a director of the Company since March 2006. Mr. Rombotis joined Cyclacel in August 1997 as our first Chief Executive Officer and has over 30 years of experience with pharmaceutical and biotechnology companies. He was previously Vice President of International Operations and Business Development; Managing Director, Europe; and Director, Japanese joint venture, at The Liposome Company, Inc. He also served as Vice President of Pharmaceuticals for Central and Eastern Europe and as Director of International Marketing at Bristol-Myers Squibb Company. He was Head of European Marketing and Sales, Head of Corporate Development and one of the first employees of Centocor, Inc. and worked in Business Development at Novartis AG. He holds a B.A. from Williams College and an M.B.A. and Master’s degree in Hospital Management with honors, from the Kellogg Graduate School of Management, where he serves on the Kellogg Biotech Advisory Board. He also serves on the Board of Trustees of BioNJ, the biotechnology industry trade group in New Jersey.

Basic Compensation

Total Annual Compensation, USD 716,247
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 265,798
Fiscal Year Total, USD 982,045

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --